Settle down guys - here are the facts !! ........
Prima has done 5 phase I studys on CVac until they found what worked. Then they completed a phase II study and are doing a second phase IIb for a ?Potency Assay? and to comply with US FDA IND. The phase III will provide ?statistical significance for US FDA and EU EMA approval?
On Abagovomab see this news
http://www.medpagetoday.com/MeetingCoverage/ASCO/26956
For Abagovomab mode of delivery(CA-125 monoclonal antibody) mimicked the previously failed phase III study of Oregovomab in 2009
See article on Oregovomab
http://jco.ascopubs.org/content/27/3/418.full
Notice the author is Dr Jonathan Berek on why Oregovomab failed. The expert call from Dr Berek on why CVac is a winner
Listen to this opinion on
http://www.investorcalendar.com/IC/CEPage.asp?ID=163542
- Forums
- ASX - By Stock
- IMM
- abagovomab vs oregovomab - facts ...
abagovomab vs oregovomab - facts ...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $428.5M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29000 | 32.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.5¢ | 42343 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1736 | 0.370 |
2 | 4400 | 0.330 |
8 | 47272 | 0.325 |
7 | 411312 | 0.320 |
2 | 37000 | 0.315 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 26940 | 1 |
0.265 | 42343 | 2 |
0.270 | 14093 | 1 |
0.275 | 11244 | 1 |
0.280 | 87163 | 3 |
Last trade - 09.46am 01/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
Day chart unavailable
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online